Roberto Valverde

Roberto Valverde is a Senior Scientist at Relay Therapeutics, specializing in structural biology and protein dynamics.3 He applies his expertise in X-ray crystallography and cryogenic electron microscopy (CryoEM) to study protein dynamics and support drug discovery efforts.3

Valverde has been involved in significant research projects at Relay Therapeutics, including:

1. The development of RLY-4008, a highly selective FGFR2 inhibitor designed for treating FGFR2-altered solid tumors.15
2. The discovery and clinical proof-of-concept of RLY-2608, a first-in-class mutant-selective PI3Kα inhibitor for treating PIK3CA-mutant cancers.24

His work contributes to advancing targeted therapies that aim to overcome limitations of existing treatments, such as off-target toxicities and resistance mutations.12

Valverde has also participated in scientific conferences, returning to BSCP2018 as an advisor4, indicating his involvement in mentoring and professional development within the scientific community.